NCT00394693View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

January 31, 2010

Study Completion Date

April 30, 2010

Conditions
Lymphoma, B-Cell
Interventions
GENETIC

Adenovirus Interferon gamma

intra-tumoral injections, 1 dose per lesion, up to 6 simultaneous lesions.

Trial Locations (6)

8090

University Hospital of Zurich, Zurich

34295

Hopital Lapeyronie, Montpellier

44093

Hopital de l'Hotel-Dieu, Nantes

60611

Northwestern University Medical School, Chicago

77030

M.D. Anderson Cancer Center, Houston

94305-5334

Stanford University School of Medicine, Stanford

Sponsors

Lead Sponsor

Transgene
All Listed Sponsors
lead

Transgene

INDUSTRY

NCT00394693 - Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma | Biotech Hunter | Biotech Hunter